60 related articles for article (PubMed ID: 23399428)
1. Depression, survival, and epidermal growth factor receptor genotypes in patients with metastatic non-small cell lung cancer.
Pirl WF; Traeger L; Greer JA; Jackson V; Lennes IT; Gallagher E; Sequist L; Temel JS
Palliat Support Care; 2013 Jun; 11(3):223-9. PubMed ID: 23399428
[TBL] [Abstract][Full Text] [Related]
2. Concomitant overexpression of EGFR and CXCR4 is associated with worse prognosis in a new molecular subtype of non-small cell lung cancer.
Al Zobair AA; Al Obeidy BF; Yang L; Yang C; Hui Y; Yu H; Zheng F; Yang G; Xie C; Zhou F; Zhou Y
Oncol Rep; 2013 Apr; 29(4):1524-32. PubMed ID: 23443279
[TBL] [Abstract][Full Text] [Related]
3. The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers.
Izar B; Sequist L; Lee M; Muzikansky A; Heist R; Iafrate J; Dias-Santagata D; Mathisen D; Lanuti M
Ann Thorac Surg; 2013 Sep; 96(3):962-8. PubMed ID: 23932319
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of genotype and number of metastatic sites in advanced non-small-cell lung cancer.
He YY; Zhang XC; Yang JJ; Niu FY; Zeng Z; Yan HH; Xu CR; Guan JL; Zhong WZ; Yang LL; Guo LH; Wu YL
Clin Lung Cancer; 2014 Nov; 15(6):441-7. PubMed ID: 25044104
[TBL] [Abstract][Full Text] [Related]
5. A clinical model for identifying radiosensitive tumor genotypes in non-small cell lung cancer.
Johung KL; Yao X; Li F; Yu JB; Gettinger SN; Goldberg S; Decker RH; Hess JA; Chiang VL; Contessa JN
Clin Cancer Res; 2013 Oct; 19(19):5523-32. PubMed ID: 23897899
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor mutations in female patients with postoperative recurrent non-small-cell lung cancer.
Na II; Kim HR; Lee JK; Park SH; Kim CH; Koh JS; Baek HJ; Choe du H
J Cancer Res Ther; 2012; 8(3):373-8. PubMed ID: 23174717
[TBL] [Abstract][Full Text] [Related]
7. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.
Kimura H; Kasahara K; Kawaishi M; Kunitoh H; Tamura T; Holloway B; Nishio K
Clin Cancer Res; 2006 Jul; 12(13):3915-21. PubMed ID: 16818687
[TBL] [Abstract][Full Text] [Related]
8. Role of EGFR SNPs in survival of advanced lung adenocarcinoma patients treated with Gefitinib.
Zhang L; Yuan X; Chen Y; Du XJ; Yu S; Yang M
Gene; 2013 Mar; 517(1):60-4. PubMed ID: 23313300
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression.
Rusch V; Klimstra D; Venkatraman E; Pisters PW; Langenfeld J; Dmitrovsky E
Clin Cancer Res; 1997 Apr; 3(4):515-22. PubMed ID: 9815714
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor genotype in plasma DNA and outcome of chemotherapy in the Chinese patients with advanced non-small cell lung cancer.
Zhuo ML; Wu MN; Zhao J; Song SW; Bai H; Wang SH; Yang L; An TT; Wang X; Duan JC; Wang YY; Guo QZ; Liu XY; Liu NH; Wang J
Chin Med J (Engl); 2011 Nov; 124(21):3510-4. PubMed ID: 22340169
[TBL] [Abstract][Full Text] [Related]
11. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms in EGFR and VEGF contribute to non-small-cell lung cancer survival in a Chinese population.
Dong J; Dai J; Shu Y; Pan S; Xu L; Chen W; Wang Y; Jin G; Ma H; Zhang M; Hu Z; Shen H
Carcinogenesis; 2010 Jun; 31(6):1080-6. PubMed ID: 20400478
[TBL] [Abstract][Full Text] [Related]
13. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
Eberhard DA; Johnson BE; Amler LC; Goddard AD; Heldens SL; Herbst RS; Ince WL; Jänne PA; Januario T; Johnson DH; Klein P; Miller VA; Ostland MA; Ramies DA; Sebisanovic D; Stinson JA; Zhang YR; Seshagiri S; Hillan KJ
J Clin Oncol; 2005 Sep; 23(25):5900-9. PubMed ID: 16043828
[TBL] [Abstract][Full Text] [Related]
14. Depression, inflammation, and epidermal growth factor receptor (EGFR) status in metastatic non-small cell lung cancer: A pilot study.
Jacobs JM; Traeger L; Eusebio J; Simon NM; Sequist LV; Greer JA; Temel JS; Pirl WF
J Psychosom Res; 2017 Aug; 99():28-33. PubMed ID: 28712427
[TBL] [Abstract][Full Text] [Related]
15. Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations.
Won YW; Han JY; Lee GK; Park SY; Lim KY; Yoon KA; Yun T; Kim HT; Lee JS
J Clin Pathol; 2011 Nov; 64(11):947-52. PubMed ID: 21725039
[TBL] [Abstract][Full Text] [Related]
16. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
Riely GJ; Pao W; Pham D; Li AR; Rizvi N; Venkatraman ES; Zakowski MF; Kris MG; Ladanyi M; Miller VA
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):839-44. PubMed ID: 16467097
[TBL] [Abstract][Full Text] [Related]
17. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.
Chou TY; Chiu CH; Li LH; Hsiao CY; Tzen CY; Chang KT; Chen YM; Perng RP; Tsai SF; Tsai CM
Clin Cancer Res; 2005 May; 11(10):3750-7. PubMed ID: 15897572
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.
Bell DW; Lynch TJ; Haserlat SM; Harris PL; Okimoto RA; Brannigan BW; Sgroi DC; Muir B; Riemenschneider MJ; Iacona RB; Krebs AD; Johnson DH; Giaccone G; Herbst RS; Manegold C; Fukuoka M; Kris MG; Baselga J; Ochs JS; Haber DA
J Clin Oncol; 2005 Nov; 23(31):8081-92. PubMed ID: 16204011
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status.
Okuma Y; Hosomi Y; Nagamata M; Yamada Y; Sekihara K; Kato K; Hishima T; Okamura T
Anticancer Res; 2013 Nov; 33(11):5057-64. PubMed ID: 24222150
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of aberrant methylation of prostaglandin E receptor 2 (PTGER2) in nonsmall cell lung cancer: association with prognosis, PTGER2 expression, and epidermal growth factor receptor mutation.
Tian L; Suzuki M; Nakajima T; Kubo R; Sekine Y; Shibuya K; Hiroshima K; Nakatani Y; Fujisawa T; Yoshino I;
Cancer; 2008 Sep; 113(6):1396-403. PubMed ID: 18666211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
